Development and characterization of PLGA-Bupivacaine and PLGA-S75:R25 Bupivacaine (Novabupi®) biodegradable implants for postoperative pain

In the hospital environment, postoperative pain is a common occurrence that impairs patient recovery and rehabilitation lengthens hospitalization time. Racemic bupivacaine hydrochloride (CBV) Novabupi® (NBV) (S (-) 75% R (+) 25% hydrochloride) are two examples of local anesthetics used in management, latter being an alternative with less deleterious effects. present study, biodegradable implants were developed using Poly(L-lactide-co-glycolide) through hot molding technique, evaluating their physicochemical properties vitro drug release. Different proportions drugs polymer tested, proportion 25%:75% was most stable for implants. Thermal spectrometric analyses performed, they revealed no unwanted chemical interactions between polymer. They also confirmed heating freeze-drying manufacturing did not interfere stability. The release results sustained release, reaching 64% NBV-PLGA 52% CBV-PLGA up to 30 days. mechanism by microscopy, which involved pores formation polymeric erosion, visualized first 72 h test. These findings suggest interesting alternatives control efficiently.